{"title":"The road to effective and accessible antibody therapies against Ebola virus","authors":"Hugues Fausther-Bovendo , Gary Kobinger","doi":"10.1016/j.coviro.2022.101210","DOIUrl":null,"url":null,"abstract":"<div><p>Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and local economies. Effective vaccines and treatments against EBOV are therefore needed to limit the impact of this deadly disease. In 2019, a hallmark clinical trial demonstrated the efficacy of monoclonal antibody (mAb) against EBOV. Despite, this recent success, survival of individuals with high viremia remains low. Effective immunotherapies against other Ebolavirus species are still under pre-clinical development. More importantly, the cost of immunotherapies is prohibitive to most individual and affected countries. Novel manufacturing and administration strategies of mAb protein or genetic information could substantially reduce the cost of immunotherapies; hence making them valuable tools against EBOV and other infectious agents.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":null,"pages":null},"PeriodicalIF":5.7000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625722000190/pdfft?md5=c0ae1bfacd20a3feddc57027002349ce&pid=1-s2.0-S1879625722000190-main.pdf","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879625722000190","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 5
Abstract
Ebola virus (EBOV) outbreaks can claim thousands of lives, cripple healthcare systems and local economies. Effective vaccines and treatments against EBOV are therefore needed to limit the impact of this deadly disease. In 2019, a hallmark clinical trial demonstrated the efficacy of monoclonal antibody (mAb) against EBOV. Despite, this recent success, survival of individuals with high viremia remains low. Effective immunotherapies against other Ebolavirus species are still under pre-clinical development. More importantly, the cost of immunotherapies is prohibitive to most individual and affected countries. Novel manufacturing and administration strategies of mAb protein or genetic information could substantially reduce the cost of immunotherapies; hence making them valuable tools against EBOV and other infectious agents.
期刊介绍：
Current Opinion in Virology (COVIRO) is a systematic review journal that aims to provide specialists with a unique and educational platform to keep up to date with the expanding volume of information published in the field of virology. It publishes 6 issues per year covering the following 11 sections, each of which is reviewed once a year: Emerging viruses: interspecies transmission; Viral immunology; Viral pathogenesis; Preventive and therapeutic vaccines; Antiviral strategies; Virus structure and expression; Animal models for viral diseases; Engineering for viral resistance; Viruses and cancer; Virus vector interactions. There is also a section that changes every year to reflect hot topics in the field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
